Allogene Therapeutics (ALLO) Capital Expenditures (2018 - 2026)
Allogene Therapeutics recorded quarterly Capital Expenditures of $9000.0 in Q1 2026, up 103.23% quarter-over-quarter from -$279000.0 in Q4 2025.
Allogene Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $9000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $9000.0; the TTM figure through Mar 2026 stood at $116000.0 (down 83.09% YoY), while the FY2025 annual figure was $107000.0, down 84.58% from the prior year.
- Capital Expenditures came in at $9000.0 for Q1 2026 at Allogene Therapeutics, up from -$279000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.9 million in Q1 2022 to a low of -$2.8 million in Q4 2022.
- A 5-year average of $200266.7 and a median of $215000.0 in 2025 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures soared 3475.0% in 2024 and tumbled 208.56% in 2025, its largest moves.
- Allogene Therapeutics' Capital Expenditures stood at -$2.8 million in 2022, then jumped by 106.42% to $181000.0 in 2023, then soared by 41.99% to $257000.0 in 2024, then sank by 208.56% to -$279000.0 in 2025, then surged by 103.23% to $9000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $9000.0, -$279000.0, and $171000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,000.00 |
| Mar 31, 2026 | 9,000.00 |
| Dec 31, 2025 | -279,000.00 |
| Dec 31, 2025 | -279,000.00 |
| Sep 30, 2025 | 171,000.00 |
| Sep 30, 2025 | 171,000.00 |
| Jun 30, 2025 | 215,000.00 |
| Jun 30, 2025 | 215,000.00 |
| Dec 31, 2024 | 257,000.00 |
| Dec 31, 2024 | 257,000.00 |
| Sep 30, 2024 | 429,000.00 |
| Sep 30, 2024 | 429,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Mar 31, 2023 | 1.04 Mn |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | -2.82 Mn |
| Dec 31, 2022 | -2.82 Mn |
| Sep 30, 2022 | 223,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Jun 30, 2022 | 1.37 Mn |
| Jun 30, 2022 | 1.37 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Dec 31, 2021 | -18.99 Mn |
| Dec 31, 2021 | -18.99 Mn |
| Sep 30, 2021 | 3.35 Mn |
| Sep 30, 2021 | 3.35 Mn |
| Jun 30, 2021 | 9.06 Mn |
| Jun 30, 2021 | 9.06 Mn |
| Mar 31, 2021 | 8.30 Mn |
| Mar 31, 2021 | 8.30 Mn |
| Dec 31, 2020 | -39.99 Mn |
| Dec 31, 2020 | -39.99 Mn |
| Sep 30, 2020 | 20.25 Mn |
| Sep 30, 2020 | 20.25 Mn |
| Jun 30, 2020 | 16.05 Mn |
| Jun 30, 2020 | 16.05 Mn |
| Mar 31, 2020 | 12.25 Mn |
| Mar 31, 2020 | 12.25 Mn |
| Dec 31, 2019 | -32.01 Mn |
| Dec 31, 2019 | -32.01 Mn |
| Sep 30, 2019 | 18.40 Mn |
| Sep 30, 2019 | 18.40 Mn |
| Jun 30, 2019 | 13.15 Mn |
| Jun 30, 2019 | 13.15 Mn |
| Mar 31, 2019 | 5.13 Mn |
| Mar 31, 2019 | 5.13 Mn |
| Dec 31, 2018 | 3.03 Mn |
| Dec 31, 2018 | 3.03 Mn |
| Sep 30, 2018 | 144,000.00 |
| Sep 30, 2018 | 144,000.00 |
| Jun 30, 2018 | 60,000.00 |
| Jun 30, 2018 | 60,000.00 |